Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6323972B2 - - Google Patents
[go: Go Back, main page]

JPS6323972B2 - - Google Patents

Info

Publication number
JPS6323972B2
JPS6323972B2 JP54104852A JP10485279A JPS6323972B2 JP S6323972 B2 JPS6323972 B2 JP S6323972B2 JP 54104852 A JP54104852 A JP 54104852A JP 10485279 A JP10485279 A JP 10485279A JP S6323972 B2 JPS6323972 B2 JP S6323972B2
Authority
JP
Japan
Prior art keywords
extract
paramecium
fraction
molecular weight
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54104852A
Other languages
Japanese (ja)
Other versions
JPS5629520A (en
Inventor
Masaka Matsubara
Tatsuo Ishihara
Tokitaka Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP10485279A priority Critical patent/JPS5629520A/en
Publication of JPS5629520A publication Critical patent/JPS5629520A/en
Publication of JPS6323972B2 publication Critical patent/JPS6323972B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

〔〕 発明の背景 技術分野 本発明は、原生単細胞動物であるパラメシウム
虫体の水溶性抽出物を有効成分とする経口健康増
進剤に関する。 さらに具体的には、本発明は、保存安定性を向
上させたパラメシウム虫体抽出物健康増進剤に関
する。 先行技術 パラメシウム虫体の水溶性抽出物が癌、肝炎お
よび難治性皮膚疾患の治療に有効(注射)である
ことが本発明者らによつて報告されている〔第35
回日本癌学会総会(昭和51年10月)、東邦医学会
雑誌、第24巻、第252―261頁(昭和52年2月)、
および第282回内科学会関東地方会(昭和53年3
月)〕。 一方、この抽出物が経口的に摂取されたときに
人体の細胞賦活作用を有することを本発明者らは
見出している(特願昭53−20720号)。すなわち、
この抽出物を内服することにより、不定愁訴を訴
えていた患者に食慾増進、体重増加、行動の活溌
化、体力増強等の効果が認められ、また風邪をひ
きにくくなりあるいは病後の体力増強ないし回服
が早くなる等の人体細胞の賦活作用が増強され
る。 問題の所在 このような経口健康増進剤として有効なパラメ
シウム虫体抽出物にも問題が無い訳ではない。す
なわち、この抽出物は保存安定性が充分に高くな
くて、次第に腐敗臭を帯びるようになるからであ
る。 〔〕 発明の概要 本発明は上述の点に解決を与えることを目的と
し、パラメシウム虫体抽出物をシクロデキストリ
ンで被覆することによつてこの目的を達成しよう
とするものである。 従つて、本発明による健康増進剤は、パラシウ
ム虫体の水溶性抽出物をシクロデキストリンで少
なくとも部分的に被覆したものを有効成分とする
こと、を特徴とするものである。 〔〕 発明の具体的説明 1 パラメシウム虫体の水溶性抽出物 パラメシウムの培養および抽出は、前記東邦医
学会雑誌、第24巻、第252―261頁に記載した通り
に、あるいはそれを適宜変更することによつて、
行なうことができる。 具体的には、たとえば、パラメシウムを水溶性
媒体中でその繁殖条件下(たとえば、牧草または
その煮汁の存在下)で培養し、虫体を夾雑物(た
とえば、繁殖用栄養源として使用した牧草)から
分離して、虫体の水性懸濁液を得る(適当な洗浄
が好ましい)。この虫体の懸濁液またはそれから
得た虫体自身(たとえば、凍結乾燥したもの)を
抽出に付す。抽出は、この虫体を水または必要に
応じてPH調節剤、緩衝剤水溶性有機溶剤、その他
の無害の無機ないし有機物質の少量を含んだ水溶
液中で、好ましくは加熱することによつて、行な
うことができる。たとえば、水性媒体(たとえば
PH4〜8程度)中で40℃〜沸点程度の温度で数十
分ないし数時間加熱する。抽残物について同様な
抽出を行なつて、各上清を集めて抽出物として利
用することがふつうである。 このようにして得られた抽出物は、ある程度の
広さの分子量分布を持つ複数成分の混合物であ
る。この抽出物の未分画物(以下、Aという)は
そのまゝ本発明の健康増進剤として利用すること
ができるが、これを高分子量分画(B)と低分子量分
画(C)とに分画してそれぞれを別個にあるいは適当
比率で混合使用して本発明の健康増進剤として利
用することもできる。分画法の一例も「東邦医学
会雑誌」第24巻、第252―261頁(1977年)に示さ
れており、また前記の特願昭53−20720号明細書
にも記載されている。具体的には、たとえば、透
析による分画(たとえば、セルローズチユーブの
透析膜で透析を行なつて、高分子分画(B)を膜内液
として、低分子分画(C)を膜外液として、それぞれ
得る。膜内外液とも、濃縮したのち、凍結乾燥す
ることができる)、ゲル過による分画(未分画
物(A)(たとえば、凍結乾燥品)水溶液を適当なゲ
ル過剤のカラムに通して、先に流出する液とし
て高分子分画(B)を、後に流出する液として低分子
分画(C)を、それぞれ得る)、限外過による分画
(未分画物(A)水溶液を適当な限外過膜を通して
流して、通過しない液として高分子分画(B)を、通
過する液として低分子分画を、それぞれ得る。)、
有機溶媒による分画(未分画物(A)水溶液に水混和
性有機溶媒を加えて、沈殿として高分子分画(B)
を、上清として低分子分画(C)を、それぞれ得る)、
その他がある。 分画の有無にかゝわらず、虫体抽出物は抽出液
ないしその精製物として、その濃縮物として(減
圧濃縮、蒸発濃縮等による)、あるいは乾燥粉末
として(凍結乾燥、減圧乾固等による)、本発明
に従つてシクロデキストリンによる被覆操作に付
す。 このような水溶性抽出物を得べきパラメシウム
原生単細胞動物はパラメシウム属に属する任意の
ものでありうるが、そのうちのいくつかを例示す
れば下記の通りである。これらのうちの一代表例
は、P.caudatumである。 Paramecium aurelia P. bursaria P. calkinsi P. caudatum P. multimicronucleatum P. polycaryum P. trichium P. woodruffi Killer Paramecium 2 安定化 本発明に従つて、上記のようにして得た抽出物
を、シクロデキストリン(CD)で少なくとも部
分的に被覆する。 一般に、CDによる被覆は包接体の形成による
もののようであるが、CD自身およびそれによる
各種化合物の包接は既に公知であつて、たとえば
「有機合成化学協会誌」、第35巻、第116―130頁
(昭和52年2月)および「澱粉科学」、第21巻、第
151頁(昭和49年)に総説がみられる。 本発明によるパラメシウム虫体抽出物のCDに
よる包接もこれら公知の方法に準じて行なえばよ
い。具体的には、たとえば、抽出物(未分画物
(A)、高分子分画(B)および低分子分画(C)の単独また
は混合物)を少量の水に溶解して、CD(α―、β
―、γ―CDのいずれでも、混合物でもよい)と
共に混練する方法、あるいはCD飽和水溶液に抽
出物を溶解して撹拌する方法、その他がある。 CDによる包接の場合は、CDと所謂ゲスト化合
物との間にそれぞれについて一定のモル比が存在
するもののようであるが、本発明でのパラメシウ
ム抽出物は低分子分画(C)といつてもかなり大きな
分子量を持つばかりでなく一定の分子量のみから
なるともいえないので、CDとの間にどのような
モル比が成り立つているのかは不明である。しか
し、本発明者らの経験によれば、CD:抽出物の
重量比は低分子分画(C)について3:1、高分子分
画(B)について3:0.001程度が好ましい結果を与
えている。この比率は必ずしもCD抽出物とがモ
ル比1:1で共存することを示す訳ではなく、ま
た抽出物がかなり分子量が大きいことを考慮すれ
ば抽出物がCDの空洞内に収容された理想的な包
接状態に在るとも考え難い。従つて、本発明(特
許請求の範囲を解釈する場合を含む)でパラメシ
ウム虫体抽出物をCDで包接するという場合は、
単に両者の処理が一般に包接化合物を与えるとい
われているものと同じであるということを意味す
るのであつて、両者が真に包接状態に在るという
ことを意味するものではない。 3 調剤化 パラメシウム虫体抽出物の安定化は上記の通り
に行なうが、これを健康増進剤として調剤化する
方法もまた合目的的な任意のものでありうる。 剤形としては液剤、散剤、顆粒剤、錠剤、その
他任意のものがあり、液剤の場合は前記のように
して得たCDと抽出物との混練物または溶液を水
その他の液状希釈剤ないし増量剤と合し、必要に
応じて甘味、芳香等を賦与すればよく、散剤の場
合はCD―抽出物混練物を粉状希釈剤ないし増量
剤たとえば澱粉、乳糖その他と合すればよい。錠
剤も常法により適当な粉状その他固形の希釈剤な
いし増量剤と共に打錠するかあるいは適当な被覆
たとえば糖衣を施せばよい。 なお、上記において「粉状の希釈剤」はCDそ
のものでもありうる。従つて、過剰量のCDを使
用して包接を行なつて過剰のCDと共に得られる
包接化合物それ自身を散剤としてあるいはそれを
打錠して錠剤として利用することもできる。 4 効能・服用量および毒性 前記のように、本発明健康増進剤は人体の細胞
賦活作用があり、具体的には、たとえば、食慾増
進、体重増加、行動の活溌化、体力増強、耐寒冒
力増大、病後体力回復促進、その他の効能が認め
られる。 服用量は、成人1日当り、低分子分画(C)で0.01
mg〜10g程度、好ましくは1mg〜1g程度、特に
好ましくは2〜6mg程度、高分子分画(B)で
0.00001mg〜1g程度、好ましくは0.0001〜0.01mg
程度、特に好ましくは0.001〜0.004mg程度、であ
る。 パラメシウム虫体水溶性抽出物は低毒性であつ
て、マウスに抽出物(A,BおよびC)を50mg/
Kg6週間および500mg/Kg4週間内服させても変
化が認められないという結果が得られている(特
願昭53−20720号明細書参照)。また、CDも低毒
性であることが報告されている(「応用薬理」第
10巻、第3号、第449―458頁(1975年))。 5 実験例 1 パラメシウムの培養、抽出および分画 (1) 培養および抽出 水100リツトルに乾燥牧草1Kgを入れて約
15分間沸騰させ、冷却後に数日放置してか
ら、パラメシウム虫体を入れて、培養する。
十分に繁殖した時に虫体を過または遠沈法
等により集め、十分に洗浄してから適当な量
の水を加えてパラメシウム懸濁液を作り、PH
5.5に調節し、約70℃の温度で1時間加熱し、
冷却後、遠心分離する。分離した上清が抽出
物である。 (2) 分画 前記のようにして遠心器で分離した上清を
減圧濃縮し、凍結乾燥し、この凍結乾燥物質
を適当量の水に溶かし、約5倍量のエタノー
ルを加えて、氷にて冷却後、遠心分離器で沈
渣(高分子分画(B))を分離し、その上清を集
めて低分子分画(C)を得る。高分子分画(C)を減
圧下に濃縮し、凍結乾燥する。また、上記高
分子分画(B)も凍結乾燥する。 2 CDによる包装 (1) 混練による方法 パラメシウム虫体抽出物の低分子画分(C)10
gと高分子画分(B)5mgとを混合し、これに10
mlの蒸留水を加えて溶解し、30gのβ―CD
を加えて撹拌すると、ペースト状になる。こ
れを乳鉢に入れて、約5時間練り合わせる。 (2) 飽和水溶液による方法 β―CDの飽和水溶液(β―CD1.85gを水
100mlに溶解する)167mlに、低分子分画(C)1
gを高分子分画(B)1mgとを溶解し、撹拌器に
入れて約5時間撹拌する。 3 調剤化 上記(1)の混練法によつて得られた包接物40gを
乳糖4960gに加えてよく混合して、均一になるよ
うにする。 あるいは、上記(2)の飽和溶液法によつて得られ
た溶液を凍結乾燥し、この乾燥物4gに乳糖496
gを加えて混合して、均一になるようにする。 このようにして得られた粉状混合物(散剤)に
は、その1gにつき8mgの包接物(CD+抽出物)
が含まれている。また、この包接物8mg中には低
分子量分画(C)は2mg、高分子分画(B)は1マイクロ
グラム含まれている。 4 CDによる包接の効果 低分子画分(C)とそのβ―CD包接物とを室温下
で蓋付ポリ容器に保管して、両試料の経時変化を
観察した。 結果は、下記の通りであつた。
[] BACKGROUND TECHNICAL FIELD OF THE INVENTION The present invention relates to an oral health-promoting agent containing a water-soluble extract of Paramecium, a protozoan unicellular animal, as an active ingredient. More specifically, the present invention relates to a paramecium worm body extract health promoting agent with improved storage stability. Prior Art The present inventors have reported that a water-soluble extract of Paramecium worm bodies is effective (injection) in the treatment of cancer, hepatitis, and intractable skin diseases [No. 35]
Annual General Meeting of the Japanese Cancer Society (October 1977), Journal of the Toho Medical Society, Volume 24, pp. 252-261 (February 1978),
and the 282nd Kanto Regional Meeting of the Japanese Society of Internal Medicine (March 1973)
Month)〕. On the other hand, the present inventors have discovered that this extract has a cell activating effect on the human body when taken orally (Japanese Patent Application No. 53-20720). That is,
By taking this extract orally, the effects of increasing appetite, increasing body weight, activating behavior, and increasing physical strength have been observed in patients who had been complaining of indeterminate complaints. The activation effect of human body cells is enhanced, such as getting dressed faster. The location of the problem Paramecium worm extract, which is effective as an oral health promoter, is not without its problems. That is, this extract does not have sufficiently high storage stability and gradually develops a putrid odor. [] Summary of the Invention The present invention aims to provide a solution to the above-mentioned problems, and attempts to achieve this object by coating a Paramecium worm body extract with cyclodextrin. Therefore, the health-promoting agent according to the present invention is characterized in that the active ingredient is a water-soluble extract of Palladium worm body at least partially coated with cyclodextrin. [] Detailed Description of the Invention 1 Water-soluble extract of Paramecium worm bodies The culture and extraction of Paramecium was carried out as described in the above-mentioned Journal of the Toho Medical Society, Vol. 24, pp. 252-261, or with appropriate modifications. By the way,
can be done. Specifically, for example, Paramecium is cultured in an aqueous medium under its propagation conditions (e.g., in the presence of grass or its broth), and the worm bodies are cultured with contaminants (e.g., grass used as a nutrient source for reproduction). (Appropriate washing is preferred) to obtain an aqueous suspension of the insect bodies. This suspension of worm bodies or the worms themselves obtained therefrom (for example freeze-dried) is subjected to extraction. Extraction is carried out by heating the insect body in water or an aqueous solution optionally containing a small amount of a PH regulator, a buffer, a water-soluble organic solvent, and other harmless inorganic or organic substances. can be done. For example, aqueous media (e.g.
(pH 4 to 8) at a temperature of 40°C to the boiling point for several tens of minutes to several hours. It is common to perform a similar extraction on the raffinate and collect the supernatants to use as extracts. The extract thus obtained is a mixture of multiple components with a certain degree of broad molecular weight distribution. The unfractionated product of this extract (hereinafter referred to as A) can be used as it is as the health promoting agent of the present invention, but it is divided into a high molecular weight fraction (B) and a low molecular weight fraction (C). It is also possible to fractionate them and use them separately or in a mixture in an appropriate ratio for use as the health-promoting agent of the present invention. An example of the fractionation method is also shown in the Journal of the Toho Medical Society, Vol. 24, pp. 252-261 (1977), and is also described in the above-mentioned Japanese Patent Application No. 1972-20720. Specifically, for example, fractionation by dialysis (for example, dialysis is performed using a dialysis membrane in a cellulose tube, and the high molecular fraction (B) is used as the inner membrane liquid and the low molecular weight fraction (C) is used as the outer membrane liquid. (Both membrane and transmembrane fluids can be concentrated and then lyophilized), fractionated by gel filtration (unfractionated product (A) (for example, lyophilized product) aqueous solution is mixed with an appropriate gel filtration agent) Pass through the column to obtain a high molecular fraction (B) as the liquid that flows out first, and a low molecular fraction (C) as the liquid that flows out later), fractionation by ultrafiltration (unfractionated material ( A) Flow an aqueous solution through a suitable ultrafiltration membrane to obtain a high molecular fraction (B) as a liquid that does not pass and a low molecular fraction as a liquid that passes.)
Fractionation using an organic solvent (unfractionated product (A)) Add a water-miscible organic solvent to the aqueous solution to precipitate the polymer fraction (B)
to obtain the low molecular weight fraction (C) as the supernatant),
There are others. Irrespective of the presence or absence of fractionation, the insect extract can be prepared as an extract or its purified product, as a concentrate (by vacuum concentration, evaporation, etc.), or as a dry powder (by freeze-drying, vacuum drying, etc.). ), subjected to a coating operation with cyclodextrin according to the invention. The Paramecium progenitor unicellular animal from which such a water-soluble extract is to be obtained may be any species belonging to the genus Paramecium, and some examples thereof are as follows. One representative example of these is P.caudatum. Paramecium aurelia P. bursaria P. calkinsi P. caudatum P. multimicronucleatum P. polycaryum P. trichium P. woodruffi Killer Paramecium 2 Stabilization According to the present invention, the extract obtained as described above is treated with cyclodextrin (CD). at least partially covered with. In general, coating with CD seems to be due to the formation of inclusion bodies, but the inclusion of CD itself and various compounds with it is already known; - p. 130 (February 1972) and "Starch Science", Vol. 21, No.
A review article can be found on page 151 (1971). Inclusion of the Paramecium worm body extract according to the present invention with CD may also be carried out according to these known methods. Specifically, for example, extracts (unfractionated
(A), high molecular weight fraction (B) and low molecular weight fraction (C) alone or as a mixture) in a small amount of water,
- or γ-CD (or a mixture may be used), a method of dissolving the extract in a saturated aqueous solution of CD and stirring, and others. In the case of inclusion by CD, there seems to be a fixed molar ratio between CD and the so-called guest compound, but the paramecium extract in the present invention is referred to as a low molecular fraction (C). Not only does it have a fairly large molecular weight, but it cannot be said that it consists only of a fixed molecular weight, so it is unclear what kind of molar ratio is established between it and CD. However, according to the experience of the present inventors, a weight ratio of CD:extract of about 3:1 for the low molecular fraction (C) and about 3:0.001 for the high molecular fraction (B) gives favorable results. There is. This ratio does not necessarily mean that the CD extract coexists in a 1:1 molar ratio, and considering that the extract has a fairly large molecular weight, it is ideal for the extract to be accommodated within the CD cavity. It is hard to imagine that it exists in a state of inclusion. Therefore, in the present invention (including when interpreting the scope of claims), when the Paramecium worm body extract is included in CD,
This simply means that the treatment of both is the same as that which is generally said to give an clathrate, but does not mean that the two are truly in an clathrate state. 3. Preparation Stabilization of the Paramecium worm body extract is carried out as described above, but any suitable method may be used to formulate it as a health-promoting agent. Dosage forms include liquids, powders, granules, tablets, and other arbitrary forms; in the case of liquids, the kneaded product or solution of CD and extract obtained as described above is mixed with water or other liquid diluent or increased volume. In the case of a powder, the CD-extract kneaded product may be mixed with a powder diluent or bulking agent such as starch, lactose, etc. Tablets may also be compressed in a conventional manner with a suitable powder or other solid diluent or filler, or may be coated with a suitable coating, such as sugar coating. Note that in the above, the "powdered diluent" may also be the CD itself. Therefore, by carrying out clathration using an excess amount of CD, the clathrate itself obtained together with the excess CD can be used as a powder, or it can be compressed into tablets. 4 Efficacy, Dosage, and Toxicity As mentioned above, the health promoting agent of the present invention has a cell activating effect on the human body, and specifically, for example, increases appetite, increases body weight, activates behavior, increases physical strength, and increases cold resistance. It has been shown to increase body weight, promote recovery of physical strength after illness, and other effects. The dose is 0.01 low molecular weight fraction (C) per day for adults.
mg to about 10 g, preferably about 1 mg to 1 g, particularly preferably about 2 to 6 mg, in the polymer fraction (B).
About 0.00001mg to 1g, preferably 0.0001 to 0.01mg
The amount is particularly preferably about 0.001 to 0.004 mg. Paramecium worm body water-soluble extract has low toxicity, and the extract (A, B and C) was administered to mice at 50 mg/day.
No change was observed even after oral administration of 500 mg/Kg for 6 weeks and 4 weeks at 500 mg/Kg (see Japanese Patent Application No. 53-20720). It has also been reported that CD has low toxicity (Applied Pharmacology, Vol.
Volume 10, No. 3, pp. 449-458 (1975)). 5 Experimental Example 1 Cultivation, extraction and fractionation of Paramecium (1) Cultivation and extraction Add 1 kg of dried grass to 100 liters of water and
Boil for 15 minutes, cool and leave for several days, then add Paramecium worm bodies and culture.
When the insects have sufficiently reproduced, collect them by filtration or centrifugation, wash them thoroughly, add an appropriate amount of water to make a paramecium suspension, and adjust the pH.
Adjust the temperature to 5.5 and heat at a temperature of about 70℃ for 1 hour.
After cooling, centrifuge. The separated supernatant is the extract. (2) Fractionation The supernatant separated using a centrifuge as described above is concentrated under reduced pressure and lyophilized. Dissolve this lyophilized substance in an appropriate amount of water, add about 5 times the amount of ethanol, and place on ice. After cooling, separate the precipitate (high molecular fraction (B)) using a centrifuge, and collect the supernatant to obtain the low molecular fraction (C). The high molecular weight fraction (C) is concentrated under reduced pressure and lyophilized. The above-mentioned polymer fraction (B) is also freeze-dried. 2 Packaging by CD (1) Method by kneading Low molecular fraction of Paramecium insect body extract (C)10
g and 5 mg of polymer fraction (B), and add 10
Add ml of distilled water and dissolve 30g of β-CD.
Add and stir to form a paste. Put this in a mortar and knead for about 5 hours. (2) Method using a saturated aqueous solution A saturated aqueous solution of β-CD (1.85g of β-CD in water
Dissolve in 100 ml) Add low molecular weight fraction (C) 1 to 167 ml.
Dissolve g with 1 mg of polymer fraction (B), place in a stirrer, and stir for about 5 hours. 3. Preparation Add 40 g of the clathrate obtained by the kneading method in (1) above to 4960 g of lactose and mix well to make it homogeneous. Alternatively, freeze-dry the solution obtained by the saturated solution method in (2) above, and add 496 g of lactose to 4 g of this dried product.
Add g and mix until homogeneous. The powder mixture (powder) thus obtained contains 8 mg of clathrates (CD + extract) per 1 g of it.
It is included. Furthermore, 8 mg of this clathrate contains 2 mg of the low molecular weight fraction (C) and 1 microgram of the high molecular weight fraction (B). 4 Effect of inclusion by CD The low molecular weight fraction (C) and its β-CD inclusion product were stored in a lidded polyethylene container at room temperature, and changes over time in both samples were observed. The results were as follows.

【表】 5 症例 (1) 78才女性 昭和53年11月5日初診。昭和53年夏ごろか
ら、全身倦怠感、食慾不振あつた。上記CD
抱接物1gを朝食前に内服させたところ、約
10日目頃から食慾が増進し、体重の増加が見
られた。また、全身の倦怠感がとれ、特に歩
行が楽になつた。 (2) 46才女性 昭和54年2月初めに風邪をひき、その後、
食慾不振、全身倦怠感、夜間の不眠があつ
た。昭和54年3月始めから、CD抱接物1g
を朝夕各々1回食前に内服させた。約1週間
目から、食慾が増進し、約20日後から不眠が
とれ、その後、倦怠感等の症状も改善され
た。 (3) 45才男性 昭和54年初めの頃から、飲酒量が減るとと
もに二日酔が強く、一方、朝が非常におきづ
らく、また肩こり、頭痛等の症状があつた。
昭和54年4月の初めから、CD抱接物1gを
朝夕食前に内服させた。約10日目から、朝の
めざめがよくなり、肩こり等の不定愁訴がと
れて来た。約2ケ月後から、飲酒量が以前と
同様になつてきた。 (4) 36才男性 急性肝炎にて入院。約3カ月後に退院した
が、退院後風邪にかかりやすく、又会社に行
つても夕方から倦怠感があり、仕事をしても
疲れを感じやすかつた。 粉体1g(2mgパラメシウム含有)を朝、
夕1回づつ内服させた所、2〜3週間後から
胸部に出ていた湿疹がとれ、1ケ月後から
段々と疲れを感じなくなつた。又仕事に対す
る意欲も出て来た。その後、風邪を引き難く
なり、数年間服用して非常に元気になつた。 現在も時々使用している。 (5) 46才男性 非常に疲れやすく又食欲がなかつた。検査
の結果、慢性肝炎で他病院にて治療し、肝機
能が良くなつて4ケ月後に退院したが、しば
らくすると同様の症状があらわれ、退院3ケ
月後に再入院し、約3ケ月間入院した。退院
の約1ケ月頃から全身の倦怠感と食慾不振で
あつたので、退院6週目から粉体0.5g(パ
ラメシウム1mg含有)を朝、夕1包づつ内服
させた。服用約1ケ月目頃から食慾増加し、
又同時に倦怠感もとれて来た。 約1年間内服し、現在元気になつている。 (6) 39才男性 大腸潰瘍にて手術をした。手術後、65Kgあ
つた体重が55Kgまで減少し、又同時に非常に
疲れやすくなつた。術後の体重も増加せず、
疲れもとれにくくなつた。術後6ケ月目から
粉体0.5g(パラメシウム1mg含有)を朝、
夕1包づつ内服した。服用しはじめてから約
2ケ月目頃から全身の倦怠感と体重増加がみ
られ、服用7ケ月目には65Kgまで体重が増加
した。 (7) 45才女性 手足の冷え、生理不順又鼻風邪を引きやす
く風呂に入ると微熱が出た。近所の病院にて
検査して子宮筋腫と診断されたが、その他特
に病気は発見されず更年期障害と云われてい
た。粉体0.5g(パラメシウム1mg含有)を
朝、夕一包づつ内服させた。 後1ケ月頃から徐々に手足があたたかくな
り、又風呂に入つても微熱が出なくなつた。
しかし、生理不順は直らず診断の約3ケ月後
に子宮筋腫の摘出を行つた。病後の回復も早
く、現在も内服している。
[Table] 5 Cases (1) A 78-year-old woman was seen for the first time on November 5, 1978. From around the summer of 1978, I began to experience general fatigue and loss of appetite. The above CD
When I took 1g of the conjugate before breakfast, approx.
From around the 10th day, appetite increased and weight increased. Additionally, I felt less tired all over my body, and walking in particular became easier. (2) A 46-year-old woman caught a cold in early February 1978, and then...
I had a loss of appetite, general fatigue, and insomnia at night. From the beginning of March 1978, 1g of CD inclusions
was administered orally once each in the morning and evening before meals. Approximately one week later, appetite for food increased, insomnia disappeared after approximately 20 days, and symptoms such as fatigue improved thereafter. (3) 45-year-old male Since the beginning of 1978, he had been drinking less and had severe hangovers, and on the other hand, had difficulty waking up in the morning, and had symptoms such as stiff shoulders and headaches.
From the beginning of April 1974, the patient was given 1 g of CD conjugate orally in the morning and before dinner. From about the 10th day onwards, I started to wake up better in the morning, and my indeterminate complaints such as stiff shoulders disappeared. After about two months, my drinking started to return to the same level as before. (4) A 36-year-old man was hospitalized with acute hepatitis. He was discharged from the hospital about three months later, but after being discharged from the hospital, he was prone to catching colds, and even when he went to work, he felt tired in the evening, and even when he worked he felt tired easily. Take 1g of powder (containing 2mg paramethium) in the morning.
After taking it orally once in the evening, the eczema that had appeared on my chest disappeared after 2 to 3 weeks, and after a month, I gradually stopped feeling tired. I also started to feel more motivated to work. After that, I became less likely to catch a cold, and after taking it for several years, I felt much better. I still use it from time to time. (5) 46-year-old male: I got tired easily and had no appetite. Tests revealed that the patient was diagnosed with chronic hepatitis and was treated at another hospital, and his liver function improved and he was discharged four months later.However, similar symptoms appeared after a while, and he was readmitted to the hospital three months after being discharged, where he remained hospitalized for about three months. Approximately one month after being discharged from the hospital, the patient had been experiencing general fatigue and poor appetite, so from 6 weeks after being discharged from the hospital, the patient was given 0.5 g of powder (containing 1 mg of paramethium) orally, one packet in the morning and one in the evening. Approximately one month after taking the drug, appetite increased.
At the same time, I started feeling tired. He has been taking oral medication for about a year and is currently doing well. (6) A 39-year-old man underwent surgery for a colon ulcer. After the surgery, my weight decreased from 65 kg to 55 kg, and at the same time, I became extremely fatigued. No weight gain after surgery
It also became difficult to get rid of fatigue. From 6 months after surgery, take 0.5g of powder (containing 1mg of paramethium) in the morning.
I took one packet in the evening. Approximately 2 months after starting to take the drug, I started to experience general fatigue and weight gain, and by the 7th month of taking the drug, my weight had increased to 65 kg. (7) 45-year-old female: Cold hands and feet, irregular menstruation, and easily catch colds, and developed a slight fever when taking a bath. She was examined at a nearby hospital and diagnosed with uterine fibroids, but no other illnesses were found, and she was diagnosed with menopausal symptoms. 0.5 g of powder (containing 1 mg of paramecium) was administered orally, once in the morning and once in the evening. After about a month, my hands and feet gradually became warmer, and I no longer had a slight fever even when I took a bath.
However, her menstrual irregularities persisted, and about three months after the diagnosis, the uterine fibroid was removed. He recovered quickly after his illness and is currently taking oral medication.

Claims (1)

【特許請求の範囲】[Claims] 1 パラメシウム虫体の水溶性抽出物をシクロデ
キストリンで少なくとも部分的に被覆したものを
有効成分とすることを特徴とする、健康増進剤。
1. A health promoting agent characterized in that the active ingredient is a water-soluble extract of Paramecium worm body at least partially coated with cyclodextrin.
JP10485279A 1979-08-17 1979-08-17 Nutrient Granted JPS5629520A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10485279A JPS5629520A (en) 1979-08-17 1979-08-17 Nutrient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10485279A JPS5629520A (en) 1979-08-17 1979-08-17 Nutrient

Publications (2)

Publication Number Publication Date
JPS5629520A JPS5629520A (en) 1981-03-24
JPS6323972B2 true JPS6323972B2 (en) 1988-05-18

Family

ID=14391812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10485279A Granted JPS5629520A (en) 1979-08-17 1979-08-17 Nutrient

Country Status (1)

Country Link
JP (1) JPS5629520A (en)

Also Published As

Publication number Publication date
JPS5629520A (en) 1981-03-24

Similar Documents

Publication Publication Date Title
CN103041173B (en) Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof
CN105687285A (en) Incense and preparation method thereof
WO2015176558A1 (en) Composition of natural vitamin c and fish scale collagen peptide and preparation method thereof
CN102743741A (en) Preparation of blattodea polypeptide, and uses of the same in anti-gram-positive bacteria and anti-gram-negative bacteria
TW200826953A (en) Agonist for healing living organisms
CN105148288A (en) Cyclodextrin-and-modified-cyclodextrin-assisted method for extracting effective ingredients of traditional Chinese medicinal materials
CN106074493A (en) The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract
JP2023505620A (en) Chinese herbal composition and its production method and use
US7780992B2 (en) Antiviral medicament
TWI336624B (en) Use of a potent product extracted from rhizomes of zingiber officinale in treating a disease associated with helicobacter pylori
CN106074464A (en) Cannabidiol application in preparation treatment gout medicine
CN106539804A (en) A kind of molecular traditional Chinese medicine cream for alleviating osteoarthritis pain and preparation method thereof
CN106362125A (en) Health-care foot patch and application method thereof
CN117357547A (en) Application of pharmaceutical composition in preparation of medicine for treating rheumatoid arthritis
CN1650846B (en) Elemene liposome and its preparation method
WO2015027730A1 (en) Traditional chinese medicine complex composite significantly increasing serum high density lipoprotein concentration, and preparation method
JPS6323972B2 (en)
CN115671139A (en) Application of Leech Extract in Development of Psoriasis External Medicine
CN115814001A (en) A topical Chinese medicinal spray for treating dermatoses
CN107114775B (en) Blood fat reducing compound based on swim bladder polypeptide of miichthys miiuy and preparation method thereof
CN106668131A (en) Earthworm composition and preparation method thereof
JPS629567B2 (en)
CN1762341A (en) Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof
CN108272991A (en) A kind of anaesthetic and its manufacturing process of removing heat from blood blood pressure lowering
CN110464742A (en) A kind of Extraction of Eucheuma gelatinae and its preparing the application in treating organs fibrosis medicine